Biopharma · FDA Approvals · Stock

RKTO Rocket One

Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to p…

Assets on file: HT-001

Catalyst calendar

Dated catalysts for RKTO, including recently decided ones.

Recent first-hand events

Every first-hand event for RKTO, newest first.

Instant stream — events appear as soon as they are filed.
Decision-gradeMaterialNotableMinor
Nov 3, 2026
01:17 PM
RKTORocket One Inc.

Rocket One (RKTO) ends HT-001 Phase 2a early after positive interim efficacy

Hoth Therapeutics ended its Phase 2a trial of topical HT-001 (aprepitant) early due to strong interim efficacy and safety data in treating EGFR inhibitor-associated skin toxicity. The company will seek FDA feedback on a potential Phase 3/pivotal program design, endpoints, and registration pathway. HT-001 remains unapproved and investigational.

Peers by market cap

Companies in the same sector closest to RKTO in market value.

RKTO FDA Calendar & Catalysts — Rocket One | Biopharma · FDA Approvals | SimianX AI